1μg (R: reducing condition, N: non-reducing condition).
Product Details
Product Details
Product Specification
Species | Cynomolgus |
Synonyms | ATC35 Antigen, OX40 Antigen, ACT35, IMD16, OX40, Receptors, OX40, ACT35 antigen, TNFRSF4, CD134, TNF Receptor Superfamily Member 4, TAX Transcriptionally-Activated Glycoprotein 1 Receptor, CD134 Antigen, TXGP1L, Tumor Necrosis Factor Receptor Superfamily, Member 4, Lymphoid Activation Antigene ACT35, OX40 Homologue, Tumor necrosis factor receptor superfamily member 4, Tax-Transcriptionally Activated Glycoprotein 1 Receptor, OX40 Cell Surface Antigen, OX40L receptor |
Accession | XP_001090870.1 |
Amino Acid Sequence | Lys28-Ala 214, with C-terminal His |
Expression System | HEK293 |
Molecular Weight | 40-55kDa (Reducing) |
Purity | >95% by SDS-PAGE |
Endotoxin | <0.1EU/μg |
Conjugation | Unconjugated |
Tag | His Tag |
Physical Appearance | Lyophilized Powder |
Storage Buffer | PBS, pH7.4. |
Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
Stability & Storage | · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles. |
Reference | 1.J Leukoc Biol . 1998 Oct;64(4):503-10. |
Background
OX40 is a member of the TNF receptor family, which is mainly known to promote effector T cell differentiation, proliferation, long-term survival, and pro-infammatory cytokines production, while inhibiting differentiation and suppressive activity of regulatory T cells (Tregs). It is expressed on activated CD4+ and CD8+ T cells, as well as on other cell types. The OX40 ligand, expressed by antigen presenting cells (APC), activates the OX40 signaling pathway which promotes a robust immune response. The interaction of OX40 with OX40 ligand results in enhanced CD4+ and CD8+ cell proliferation, stimulated cytokine production, and increased survival of antigen specific memory T cell. OX40 expression was revealed as an unfavorable prognostic marker and might be a target for immunotherapy in the future. OX40 was identified as a novel molecule in EC; its elevated expression tends to signify favorable clinical outcomes. As a second immune checkpoint, OX40 may have potential implications for the prognosis and immunomodulation of EC patients. In mice, the absence of OX40 has been shown to cause a strong reduction in the number of effector memory CD4+ cells. Furthermore, the CD8+ response was reduced and tumor growth was accelerated. Accordingly, it is comprehensible that the immune-stimulating properties of OX40 agonists could overcome some of the immunosuppressive properties within tumor environment.
Picture
Picture
SDS-PAGE
ELISA

Immobilized OX40/TNFRSF4/CD134 His Tag, Cynomolgus (Cat. No. UA010842)at 2.0μg/mL (100μL/well) can bind Anti-Human OX40 Monoclonal Antibody (Ivuxolimab) with EC50 of 44.11-54.17ng/mL.
